MedTrace Logo

Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors

NCT06231277 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-01-30

No results posted yet for this study

Summary

The goal of this clinical trial is to about in Patients With Advanced Solid Tumors. The main question\[s\] it aims to answer are:

* question 1:Evaluating the tolerability of BH002 injection in Chinese patients with advanced solid tumors
* question 2:Obtain the pharmacokinetic (PK) characteristics of BH002 injection in Chinese patients with advanced solid tumors

Conditions

Interventions

DRUG

BH002

Every 21 days constitutes a treatment cycle, and administration begins on the first day of each cycle

Sponsors & Collaborators

  • Zhuhai Beihai Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Dingwei Ye, PI · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2023-03-10
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06231277 on ClinicalTrials.gov